GlassScriptPhysician profile
Heather R Shultz
NPI 1548445588
$5,490.74
in general payments reported to CMS, 2019-2025
31 companies · $693 in 2025
The $693 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,803 · 2022: $1,331 · 2023: $710 · 2024: $954 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.94 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $944.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $796.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $545.94 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $431.29 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $400.12 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $348.30 | 2021-2025 | Imdelltra (Amg757), Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.83 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $208.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $207.02 | 2021-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.03 | 2022-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $130.85 | 2021 | |
| Esperion Therapeutics, INC. | $118.26 | 2021-2025 | Nexletol |
| Pfizer INC. | $113.93 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $83.65 | 2023-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $75.40 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $68.32 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $64.64 | 2023-2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $63.53 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.71 | 2022 | |
| Amarin Pharma, INC. | $61.04 | 2021 | |
| Dexcom, INC. | $49.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.81 | 2022-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $41.70 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.58 | 2024-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $30.06 | 2021 | |
| Inogen, INC. | $29.87 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.54 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $18.39 | 2021 | |
| Medtronic, INC. | $14.14 | 2022 | |
| Mylan Specialty L.P. | $12.05 | 2021 | |
| Eisai INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.